Consuming alcohol with Barinez does not cause any harmful side effects.
CONSULT YOUR DOCTOR
Barinez is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
CONSULT YOUR DOCTOR
Barinez is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
SAFE
Barinez does not usually affect your ability to drive.
UNSAFE
Barinez is probably unsafe to use in patients with kidney disease and should be avoided. Please consult your doctor.
SAFE IF PRESCRIBED
Barinez is safe to use in patients with liver disease. No dose adjustment of Barinez is recommended.
Barinez may not be recommended in patients with severe liver disease due to lack of information and research. Therefore, it is important to consult the doctor.
Medicine Overview of Barinez 2mg Tablet
Introduction
Barinez is a Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis. It helps decrease pain, tenderness and swelling in the joints by reducing inflammation. It also helps slow the progression of bone and joint damage.
Barinez may be prescribed alone or in combination with another drug. The tablets can be taken with or without food, but it is best to take them at the same time each day. Your dose will depend on your condition and what other medicines you are taking. You should use it as your doctor tells you to. Do not stop taking this medicine unless your doctor tells you to because your condition could get worse.
The most common side effects of Barinez include throat and nose infections, nausea and viral infection. You may also get cold sores, feel sick or have symptoms of a cold like stuffy nose, sneezing and sore throat. There are other less common side effects, some of them serious, including blood clots and tears in the stomach or intestine wall. These need urgent medical attention. If you have concerns regarding side effects, talk to your doctor.
You may need blood tests before you are given this medicine and you should not start taking it if you have any kind of infection. Make sure you talk to your doctor before starting treatment if you have, or have ever had, tuberculosis, shingles, kidney or liver disease, hepatitis B or C, or blood clots in your legs or lungs. Barinez can make you more likely to get infections or may worsen any current infections so avoid contact with people who have things you might catch (e.g., chickenpox, measles or flu). This medicine is not suitable for children under 18 years old and you should not use it if you're pregnant or breastfeeding, unless your doctor feels the benefit is greater than the risk. Your doctor may need to examine you on a regular basis.
Uses of Barinez
Rheumatoid arthritis
Side effects of Barinez
Common
Nausea
Upper respiratory tract infection
How to use Barinez
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Barinez may be taken with or without food, but it is better to take it at a fixed time.
How Barinez works
Barinez is Janus kinase inhibitor. It works by blocking the action of the enzyme, Janus kinase. This decreases inflammation and joint damage in rheumatoid arthritis.
Quick Tips
Barinez is used alone or in combination with methotrexate for the treatment of rheumatoid arthritis that did not improve with other anti-rheumatic drugs.
It may take 3 to 6 months to feel the maximum effect of this medication. Keep taking it as prescribed.
Your doctor may get regular blood tests done to monitor your liver function, kidney function, blood counts or cholesterol level.
Barinez can make it a bit harder for people to fight off infections. Inform your doctor if you have symptoms of an infection such as fever, chills, cough, and muscle aches.
Your doctor may get TB (tuberculosis) skin test and a chest X-ray before starting treatment with this medication.
Inform your doctor if you are pregnant, planning to conceive, or breastfeeding.
Brief Description
Indication
Rheumatoid Arthritis
Adult Dose
Rheumatoid Arthritis
Indicated for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies
May be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs)
2 mg PO qDay
Mode of Action
Janus kinases (JAKs) pathways inhibitor; JAK consists of a group of intracellular tyrosine kinases that transmit signals from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoieses and immune cell function
Within the signaling pathway, JAKs phosphorylate and activate signal transducers and activators of transcription (STATs), which modulate intracellular activity including gene expression; baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs
Precaution
Serious and sometimes fatal infections may develop owing to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens reported; may cause reactivation of latent TB or viral infections (see Black Box Warnings and Dosing Considerations)
Consider risks and benefits before initiating in patients with chronic or recurrent infection, history of serious or opportunistic infection, underlying conditions predisposing them to infection, or patients who have been exposed to tuberculosis or have resided or traveled in areas of endemic tuberculosis or mycoses (see Black Box Warnings)
Consider TB therapy for patients with a negative test for latent TB but who have risk factors for TB infection; consultation with a physician with expertise in TB recommended to aid in decision about whether initiating anti-TB therapy is appropriate
If a new infection develops during treatment, promptly initiate diagnostic tests appropriate for an immunocompromised patient; if necessary, initiate appropriate antimicrobial therapy and closely monitor; interrupt baricitinib therapy if patient unresponsive to treatment
If herpes zoster occurs, interrupt treatment until episode resolves
Malignancies were observed in clinical studies; non-melanoma skin cancers (NMSCs) reported; periodic skin examination is recommended for patients who are at increased risk for skin cancer
Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy; unknown impact on chronic viral hepatitis reactivation
Increased incidence of thrombosis, including DVT and PE, observed compared with placebo; caution in patients at increased risk of thrombosis (see Black Box Warnings)
Gastrointestinal perforation reported in clinical studies, although the role of JAK inhibition in these events is unknown
May increase incidence of neutropenia, lymphopenia, anemia, or elevated LFTs or lipids; monitor laboratory values at baseline and periodically during treatment
Pregnancy
Data in pregnant women are insufficient to inform a drug-associated risk for major birth defects or miscarriage
Animal studies
In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than ~20 and 84 times the maximum recommended human dose (MRHD), respectively, resulted in reduced fetal body weights, increased embryo lethality (rabbits only), and dose-related increases in skeletal malformations
Lactation
Unknown if distributed in human breast milk
Baricitinib is present in the milk of lactating rats
Owing to species-specific differences in lactation physiology, the clinical relevance of these data are not clear
Because of the potential for serious adverse reactions in nursing infants, advise women not to breastfeed while taking baricitinib
Interaction
Avoid use of live vaccines; update immunizations in agreement with current immunization guidelines before initiating
Coadministration with strong OAT3 inhibitors may increase baricitinib systemic exposure
ফার্মেসীর জন্য পাইকারি দামে ঔষধ কিনতে রেজিস্টেশন করুন
The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.